FLURANDRENOLIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; metabolites are inactive or weakly active. |
| Excretion | Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily to albumin and corticosteroid-binding globulin (CBG; transcortin). |
| Volume of Distribution | Vd estimated at 0.5–1.0 L/kg; clinical meaning: indicates moderate tissue distribution, not extensively sequestered. |
| Bioavailability | Topical: bioavailability is variable (1–10% systemically absorbed through intact skin; higher with occlusion, damaged skin, or prolonged use). Oral: not applicable; not administered systemically. |
| Onset of Action | Topical: onset of anti-inflammatory effect within 12–24 hours; occlusive dressing may enhance penetration and reduce onset time. |
| Duration of Action | Topical: duration of action up to 12–24 hours per application; clinical notes: frequency depends on severity; occlusion prolongs effect. |
| Molecular Weight | 436.52 |
Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use; systemic absorption minimal. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption minimal. |
| Pediatric use | Apply sparingly to affected area once or twice daily; limit treatment duration and avoid occlusion due to increased systemic absorption risk. |
| Geriatric use | Use lowest effective dose for shortest duration; skin atrophy risk increased with prolonged use. |
| 1st trimester | Avoid use during first trimester due to potential teratogenicity; limited human data, but corticosteroids associated with oral clefts. |
| 2nd trimester | Use only if clearly needed; monitor fetal growth as corticosteroids may cause intrauterine growth restriction. |
| 3rd trimester | Use with caution; may cause adrenal suppression in neonate if used near term. |
Clinical note
Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).
| Placental transfer | Flurandrenolide is a corticosteroid; placental transfer occurs, but extent depends on formulation and application. Systemic absorption from topical use is low (<1%), limiting fetal exposure. |
| Breastfeeding | Topical application likely results in negligible systemic absorption; however, avoid application to breast area to prevent infant ingestion. Use lowest potency and shortest duration possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to flurandrenolide or any componentUntreated bacterial, fungal, or viral skin infectionsPerioral dermatitisRosacea
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes., Local irritation, allergic contact dermatitis, and skin atrophy may occur., Avoid prolonged use on face, intertriginous areas, or under occlusive dressings., Use with caution in patients with skin infections or impaired circulation. |
| Food/Dietary | No known food interactions with topical flurandrenolide. Systemic absorption is minimal, so dietary restrictions are not required. |
Loading safety data…
| Lactation Rating | L2 (Safer if used appropriately) |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used as directed. However, high potency formulations or prolonged use over large areas may increase systemic absorption and potential risk. Flurandrenolide is a medium potency corticosteroid. Animal studies showed cleft palate and growth retardation at high doses. Human data are limited; avoid high doses and extensive areas during first trimester. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (especially in prolonged use), signs of adrenal suppression (e.g., fatigue, hypotension). Fetal growth monitoring if used extensively. Reassess skin condition regularly to minimize exposure. |
| Fertility Effects | No known effects on fertility in humans. High-dose systemic corticosteroids may impair fertility in animal studies, but topical use is unlikely to affect reproductive function. |
| Clinical Pearls |
| Flurandrenolide is a group V (moderate potency) topical corticosteroid. Use limited duration (≤2 weeks) on thin skin areas (face, intertriginous) to avoid atrophy. Avoid occlusive dressings unless directed, as they increase absorption. Do not use on open wounds or infected lesions without appropriate antimicrobial therapy. |
| Patient Advice | Apply a thin film only to affected areas; do not use on large body surface areas. · Wash hands after application unless treating hands. · Do not cover with bandages or dressings unless directed by your doctor. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use for longer than prescribed; report if no improvement after 2 weeks. · Inform your doctor if you are pregnant, nursing, or have diabetes. |